Registration Strip Icon for alerts Regístrate para obtener alertas en tiempo real, cartera personalizada y movimientos del mercado.

0RQE

Idorsia (0RQE)

Idorsia Ltd
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:LSE:0RQE
FechaHoraFuenteTítuloSímboloCompañía
01/05/202411:00UK RegulatoryIdorsia increases the consent fee in connection with the proposed restructuring of the 2024 convertible bondLSE:0RQEIdorsia Ltd
26/04/202400:00UK RegulatoryJERAYGO (aprocitentan) recommended for approval in Europe for the treatment of resistant hypertensionLSE:0RQEIdorsia Ltd
23/04/202400:00UK RegulatoryIdorsia publishes an invitation to a bondholder meetingLSE:0RQEIdorsia Ltd
17/04/202400:00UK RegulatoryIdorsia publishes a Financial Status required for an upcoming bondholder meetingLSE:0RQEIdorsia Ltd
11/04/202400:00UK RegulatoryIdorsia takes steps to address short-term liquidity needsLSE:0RQEIdorsia Ltd
22/03/202401:00UK RegulatoryIdorsia thanks Guy Braunstein for his years of service as he retiresLSE:0RQEIdorsia Ltd
20/03/202401:00UK RegulatoryUS FDA approves Idorsia’s once-daily TRYVIO (aprocitentan) – the first and only endothelin receptor antagonist for the treatment of high blood pressure not adequately controlled in combination with other antihypertensivesLSE:0RQEIdorsia Ltd
18/03/202401:00UK RegulatoryIdorsia and Viatris successfully close the transaction for the global research and development collaborationLSE:0RQEIdorsia Ltd
28/02/202400:00UK RegulatoryIdorsia and Viatris enter into a significant global research and development collaborationLSE:0RQEIdorsia Ltd
 Showing the most relevant articles for your search:LSE:0RQE